|
For pharmaceutical, human and agricultural biotechnology, and medical products, technology and devices companies, the life sciences industry is changing at an unprecedented rate. Growing customer needs, revolution in R&D and drug discovery, shifting markets and sources, evolution of the biotech sector, emergence of the specialty and generic sectors, worldwide efforts to control healthcare costs, and an evolving regulatory and compliance environment create both opportunities and challenges for life sciences companies.  | | The Future of the Life Sciences Industries The distinction between biotech and pharmaceutical firms will erode over the next decade, according to a white paper by the Economist Intelligence Unit and Deloitte Touche Tohmatsu. The report predicts biotech and medical device firms will grow more quickly than pharmaceuticals, with the fastest growth in Asian markets. The survey asked senior executives in the Life Sciences industries about the strategic priorities over the next 10 years, where the main challenges lie and how they intend to seize opportunities. Read the The Future of the Life Sciences Industries: Strategies for Success in 2015. |
 .gif)
| 
